Under these conditions, adaptive mechanisms must be triggered to maintain chemoresistance; in this regard, targeting the eIF4F complex and its associated signaling pathways have emerged as potential therapeutic strategies to overcome ER+ cancer chemoresistance [38]. This evidence concerns the gene EIF4G1 and cancer.